Women at risk for gonorrhea: comparison of rosaramicin and ampicillin plus probenecid in the eradication of Neisseria gonorrhoeae, Chlamydia trachomatis and genital mycoplasmas.

Abstract

Rosaramicin is a macrolide antibiotic with activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and the genital mycoplasmas Ureaplasma urealyticum and Mycoplasma hominis. Its efficacy in the treatment of genital infections was evaluated and compared with that of single-dose ampicillin plus probenecid in women with known, or suspected, uncomplicated gonococcal infection. Isolation rates for N. gonorrhoeae, C. trachomatis, U. urealyticum, and M. hominis were 72%, 44%, 95%, and 65%, respectively. Rosaramicin cured 24 (89%) of 27 gonococcal infections and 11 (92%) of 12 chlamydial infections. It transiently reduced the carriage of U. urealyticum but had little effect on carriage of M. hominis. Rosaramicin may be of value in the treatment of concurrent gonococcal and chlamydial infections when tetracycline is contraindicated.

• Authors: B E Batteiger, B E Zwickl, M L French, R B Jones
• Journal: Sexually transmitted diseases (Sex Transm Dis) 1985 Jan-Mar Vol. 12 Issue 1 Pg. 1-4 ISSN: 0148-5717 [Print] United States
• PMID: 3890223 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Combinations
• Leucomycins
• Ampicillin
• Probenecid

Topics

• Adolescent
• Adult
• Ampicillin (therapeutic use)
• Chlamydia Infections (drug therapy)
• Chlamydia trachomatis
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations
• Female
• Gonorrhea (drug therapy)
• Humans
• Leucomycins (therapeutic use)
• Mycoplasma Infections (drug therapy)
• Probenecid (therapeutic use)
• Random Allocation
• Risk